Spineart wins FDA approval for BAGUERA C cervical disc, GIMV says

• GIMV portfolio company Spineart secured FDA clearance for its BAGUERA C cervical disc for 1- and 2-level contiguous use in the US.
• Approval broadens US access to a motion-preserving alternative to spinal fusion for cervical disc disease.
• Decision backed by two US randomized trials with nearly 600 patients; more than 80,000 devices sold globally.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GIMV NV published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.